Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL1498068 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrogen Sulfide SCHEMBL11572294 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrogen Sulfide SCHEMBL1498065 | 0.98 | RNPEP (0.50) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Water SCHEMBL7531314 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL232286 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Water SCHEMBL7531312 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Iodide SCHEMBL3660488 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL349508 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| Iodide SCHEMBL3660485 | 0.96 | RNPEP (0.48) | RNPEPLMNAALDH1A1NPSR1KDM4E | |
| SCHEMBL748892 | 0.96 | RNPEP (0.52) | RNPEPLMNAALDH1A1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-20120172324-A1 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF AGENT-INDUCED LIVER TOXICITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-05 | — | — | US | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011035005-A2 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF AGENT-INDUCED LIVER TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | RNPEP 929/4885LMNA 1190/4885ALDH1A1 1185/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | RNPEP 2009/4885LMNA 1677/4885ALDH1A1 68/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | RNPEP 2083/4885LMNA 1646/4885ALDH1A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.